Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report

被引:6
|
作者
Zhu, Shu-Guang [1 ]
Li, Hai-Bo [1 ]
Dai, Tian-Xing [1 ]
Li, Hua [1 ]
Wang, Guo-Ying [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Dept Hepat Surg & Liver Transplantat, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China
[2] Guangzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou 510220, Guangdong, Peoples R China
关键词
Intrahepatic cholangiocarcinoma; Lymph node metastasis; Neoadjuvant therapy; Immunotherapy; Chemotherapy; Surgical resection; Case report; DIAGNOSIS;
D O I
10.12998/wjcc.v10.i27.9743
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND The prognosis of intrahepatic cholangiocarcinoma (ICC) with lymph node metastasis is poor. The feasibility of surgery is not certain, which is a contraindication according to the National Comprehensive Cancer Network guidelines. The role of immunotherapy as a neoadjuvant therapy for ICC is not clear. We herein describe a case of ICC with lymph node metastasis that was successfully treated with neoadjuvant therapy. CASE SUMMARY A 60-year-old man with a liver tumor was admitted to our hospital. Enhanced computed tomography and magnetic resonance imaging revealed a spaceoccupying lesion in the right lobe of the liver. Multiple subfoci were found around the tumor, and the right posterior branch of the portal vein was invaded. Liver biopsy indicated poorly differentiated cholangiocytes. According to the American Joint Committee on Cancer disease stage classification, ICC with hilar lymph node metastasis (stage IIIB) and para-aortic lymph node metastasis was suspected. A report showed that two patients with stage IIIB ICC achieved a complete response (CR) 13 mo and 16 mo after chemotherapy with a PD-1 monoclonal antibody. After multidisciplinary consultation, the patient was given neoadjuvant therapy, surgical resection and lymph node dissection, and postoperative adjuvant therapy. After three rounds of PD- 1 immunotherapy ( camrelizumab) and two rounds of gemcitabine combined with cisplatin regimen chemotherapy, the tumor size was reduced. Therefore, a partial response was achieved. Exploratory laparotomy found that the lymph nodes of Group 16 were negative, and the tumor could be surgically removed. Therefore, the patient underwent right hemihepatectomy plus lymph node dissection. The patient received six rounds of chemotherapy and five rounds of PD-1 treatment postoperatively. After 8 mo of follow-up, no recurrence was found, and a CR was achieved. CONCLUSION Neoadjuvant therapy combined with surgical resection is useful for advanced- stage ICC. This is the first report of successful treatment of stage IIIB ICC using neoadjuvant therapy with a PD-1 inhibitor.
引用
收藏
页码:9743 / 9749
页数:7
相关论文
共 50 条
  • [31] Psoriasis following PD-1 inhibitor therapy: features and treatment
    O'Connor, P.
    Dutz, J. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E267 - E267
  • [32] PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
    Zhang, Hong-Qiang
    Huang, Chang-Zhi
    Wu, Jing-Yu
    Wang, Zhen-Ling
    Shao, Yu
    Fu, Zan
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (14) : 4669 - 4675
  • [33] PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
    Hong-Qiang Zhang
    Chang-Zhi Huang
    Jing-Yu Wu
    Zhen-Ling Wang
    Yu Shao
    Zan Fu
    World Journal of Clinical Cases, 2022, (14) : 4669 - 4675
  • [34] Successful Treatment of Metastatic Primary Cutaneous Adnexal Carcinoma With a PD-1 Inhibitor
    Patel, Janmesh D.
    Pozorski, Vincent J.
    Tavberidze, Nika
    Buehler, Darya G.
    Huang, Wei
    Bennett, Daniel D.
    Ma, Vincent T.
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (08) : 323 - 327
  • [35] Successful liver transplantation with ctDNA clearance after PD-1 inhibitor plus FOLFOX-HAIC treatment in HCC: A case report
    Zhao, Yuanyuan
    Chen, Dong
    Yang, Bo
    Xu, Jing
    Wang, Lu
    Huang, Guobin
    Wei, Lai
    Chen, Zhishui
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [36] Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report
    Xu, Li
    Tao, Ning-ning
    Liang, Bin
    Li, Dao-wei
    Li, Huai-chen
    Su, Li-li
    THORACIC CANCER, 2022, 13 (03) : 502 - 505
  • [37] Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    Li, Qiang
    Wang, Xiaolan
    Li, Deju
    Liu, Yulong
    Liu, Kangshou
    Liang, Junjie
    Sun, Jian
    Jiang, Quan
    Li, Jiexing
    Liu, Zhilong
    Gong, Jian
    Xiang, Leyang
    Jia, Zhidong
    Chen, Zhiwei
    Cao, Mingrong
    Jiang, Yuchuan
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2024, (207):
  • [38] PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report
    Lim, Olivia
    Maher, Eamonn
    Miller, Daniel D.
    DRUGS IN R&D, 2024, 24 (02) : 353 - 357
  • [39] Tattoo reactions under PD-1 inhibitor therapy - a case study
    Wolf, C.
    Schubert, S.
    Alter, M.
    Angela, Y.
    Gutzmer, R.
    Stadler, R.
    Stephan, S. A.
    Hoffmann, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 59 - 60
  • [40] Acquired Perforating Dermatosis Induced by PD-1 Inhibitor: A Case Report
    Liu, Xiaoyan
    Wang, Huayang
    Wan, Yinsheng
    Guo, Ying
    Shan, Shi-Jun
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (12) : 942 - 944